Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178

1.

Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ.

J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248-1. doi: 10.1016/j.jhep.2017.07.033. [Epub ahead of print]

PMID:
28844936
2.

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.

Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK.

Hepatol Int. 2015 Apr;9(2):224-30. doi: 10.1007/s12072-015-9612-6. Epub 2015 Mar 12.

PMID:
25788197
3.

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ.

J Hepatol. 2014 Dec;61(6):1228-37. doi: 10.1016/j.jhep.2014.07.019. Epub 2014 Jul 18.

4.

Impact of a formal mentoring program on academic promotion of Department of Medicine faculty: a comparative study.

Morrison LJ, Lorens E, Bandiera G, Liles WC, Lee L, Hyland R, Mcdonald-Blumer H, Allard JP, Panisko DM, Heathcote EJ, Levinson W; Faculty Development Committee, Department Of Medicine, Faculty Of Medicine, University Of Toronto.

Med Teach. 2014 Jul;36(7):608-14. doi: 10.3109/0142159X.2014.899683. Epub 2014 May 7.

PMID:
24804918
5.

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.

Hepatology. 2013 Sep;58(3):872-80. doi: 10.1002/hep.26436. Epub 2013 Jul 29.

PMID:
23553752
6.

Disease burden of chronic hepatitis B among immigrants in Canada.

Wong WW, Woo G, Heathcote EJ, Krahn M.

Can J Gastroenterol. 2013 Mar;27(3):137-47.

7.

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.

PMID:
23268517
8.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ.

Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.

PMID:
23234725
9.

The impact of infection on population health: results of the Ontario burden of infectious diseases study.

Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, Allen VG, Bayoumi AM, Fazil A, Fisman DN, Gershon AS, Gournis E, Heathcote EJ, Jamieson FB, Jha P, Khan KM, Majowicz SE, Mazzulli T, McGeer AJ, Muller MP, Raut A, Rea E, Remis RS, Shahin R, Wright AJ, Zagorski B, Crowcroft NS.

PLoS One. 2012;7(9):e44103. doi: 10.1371/journal.pone.0044103. Epub 2012 Sep 4.

10.

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants.

Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI; Italian PBC Genetics Study Group, Lazaridis KN, Seldin MF, Siminovitch KA.

Hum Mol Genet. 2012 Dec 1;21(23):5209-21. doi: 10.1093/hmg/dds359. Epub 2012 Aug 29.

11.

Combining semiquantitative measures of fibrosis and qualitative features of parenchymal remodelling to identify fibrosis regression in hepatitis C: a multiple biopsy study.

Pattullo V, Thein HH, Heathcote EJ, Guindi M.

Histopathology. 2012 Sep;61(3):473-87. doi: 10.1111/j.1365-2559.2012.04249.x. Epub 2012 Mar 27.

PMID:
22448672
12.

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.

Hepatology. 2012 Jul;56(1):67-75. doi: 10.1002/hep.25636. Epub 2012 Apr 25.

PMID:
22307831
13.

Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype.

McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch K.

Gastroenterology. 2012 May;142(5):1122-1131.e1. doi: 10.1053/j.gastro.2012.01.028. Epub 2012 Jan 25.

PMID:
22285807
14.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
15.

Clinical trials and their translation in hepatology: past, present, and future.

Heathcote EJ.

Hepatology. 2012 Aug;56(2):399-410. doi: 10.1002/hep.25557. Epub 2012 Jul 10. No abstract available.

PMID:
22213049
16.

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N.

Hepatology. 2011 Nov;54(5):1538-46. doi: 10.1002/hep.24549.

17.

Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention.

Pattullo V, Alkazaz N, Sockalingam S, Heathcote EJ.

J Obes. 2011;2011:942516. doi: 10.1155/2011/942516. Epub 2011 May 23.

18.

Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes.

Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ.

Liver Int. 2011 Aug;31(7):1028-38. doi: 10.1111/j.1478-3231.2011.02549.x. Epub 2011 May 25.

PMID:
21733093
19.

Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey.

Sam JJ, Heathcote EJ, Wong DKh, Wooster DL, Shah H.

Can J Gastroenterol. 2011 Mar;25(3):127-34.

20.

Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition.

Arendt BM, Mohammed SS, Ma DW, Aghdassi E, Salit IE, Wong DK, Guindi M, Sherman M, Heathcote EJ, Allard JP.

Curr HIV Res. 2011 Mar;9(2):128-35.

PMID:
21434863

Supplemental Content

Loading ...
Support Center